These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2260879)

  • 1. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
    Kimura E; Kobayashi S; Terashima Y
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and clinical research of computer aided multivariate pattern analysis system (CAMPAS) OV-1 for diagnosis of ovarian carcinoma].
    Kobayashi S; Murae M; Kimura E
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):241-8. PubMed ID: 8492011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating mucins as tumor markers in ovarian cancer (review).
    Devine PL; McGuckin MA; Ward BG
    Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
    Yakushiji M; Nishimura H
    Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis: tumor marker].
    Inaba N; Takamizawa Y; Ota J; Fukazawa K
    Gan No Rinsho; 1990 Aug; 36(10):1123-7. PubMed ID: 2214148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
    Xi MR; Peng ZL; Cao ZY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
    Ito K; Udagawa Y; Nozawa S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The combination assay of tumor markers by multivariate analysis for improvements of the diagnostic precision in malignancies].
    Okajima Y; Fukasawa I; Inaba N
    Nihon Rinsho; 1996 Jun; 54(6):1659-63. PubMed ID: 8691626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Field trial of the early detection in patients with ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Kouda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1743-9. PubMed ID: 2480393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New technology of diagnosis of ovarian cancer].
    Terashima Y
    Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H; Tatra G; Bieglmayer C
    Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.